Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440053 | 0.86 | SUCNR1 (0.50) | PTGDR2FFAR1PLA2G10PLA2G2ASHMT1 | |
| SCHEMBL4440751 | 0.84 | KAT6A (0.45) | PTGDR2FFAR1PTGDR | |
| SCHEMBL4437914 | 0.83 | MMP1 (0.50) | PTGDR2 | |
| SCHEMBL4439770 | 0.82 | FFAR1 (0.50) | FFAR1PPARG | |
| SCHEMBL4428870 | 0.81 | GRIN2D (0.41) | PTGDR2 | |
| SCHEMBL4431262 | 0.81 | FFAR1 (0.52) | FFAR1PLA2G10PLA2G2A | |
| SCHEMBL4428893 | 0.80 | PPARG (0.48) | PTGDR2FFAR1PPARG | |
| SCHEMBL4428862 | 0.80 | FFAR1 (0.43) | PTGDR2FFAR1PLA2G10PLA2G2A | |
| SCHEMBL4440778 | 0.79 | SHMT1 (0.48) | PTGDR2FFAR1PLA2G10PLA2G2ASHMT1 | |
| SCHEMBL4430126 | 0.79 | FFAR1 (0.50) | PTGDR2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121591-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | PTGDR2 626/4885FFAR1 30/4885PTGDR 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.